Skip to main content
Year archive

BioArctic — 2022 filings

All 36 regulatory filings released by BioArctic (BIOA) in 2022, sourced directly from the official regulator.

36 Filings
2022 Period
2022 filings (36)
Filing Released Lang
Antal aktier och röster i BioArctic AB (publ) per den 30 november 2022
Declaration of Voting Results & Voting Rights Announcements
2022-11-30 Swedish
Number of shares and votes in BioArctic AB (publ) as of November 30, 2022
Share Issue/Capital Change
2022-11-30 English
Resultaten från fas 3-studien Clarity AD med lecanemab i tidig Alzheimers sjukdom publicerade i tidskriften New England Journal of Medicine
Regulatory Filings
2022-11-30 Swedish
Full results of lecanemab Phase 3 confirmatory Clarity AD study for early Alzheimer’s disease published in the New England Journal of Medicine
Regulatory Filings
2022-11-30 English
BioArctics partner Eisai presenterar resultat från fas 3-studien Clarity AD med lecanemab på Alzheimerkonferensen CTAD
Regulatory Filings
2022-11-30 Swedish
BioArctic’s partner Eisai presents results of lecanemab Phase 3 confirmatory Clarity AD study for Early Alzheimer’s disease at CTAD conference
Earnings Release FY 2022
2022-11-30 English
Major Shareholding Notification 2022
Major Shareholding Notification
2022-10-26 English
BioArctic’s founders intend to divest minor part of their shareholding
Major Shareholding Notification
2022-10-25 English
BioArctics grundare har för avsikt att sälja en mindre del av sitt aktieinnehav
Major Shareholding Notification
2022-10-25 Swedish
Earnings Release 2022
Earnings Release 9M 2022
2022-10-20 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Q3 2022
2022-10-20 English
BioArctic presenterar valberedningen
Governance Information
2022-10-18 Swedish
BioArctic presents Nomination Committee
AGM Information
2022-10-18 English
Lecanemab uppnådde både det primära och alla sekundära effektmått i fas 3-studien Clarity AD i tidig Alzheimers sjukdom med hög statistisk signifikans
Regulatory Filings
2022-09-28 Swedish
Lecanemab phase 3 Clarity AD study in early Alzheimer’s disease meets primary and all key secondary endpoints with high statistical significance
Earnings Release FY 2022
2022-09-28 English
Earnings Release 2022
Earnings Release Q2 2022
2022-07-12 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Q2 2022
2022-07-12 English
The FDA accepts BLA and grants priority review for lecanemab for treatment of early Alzheimer’s disease under the accelerated approval pathway
Regulatory Filings
2022-07-06 English
FDA accepterar registreringsansökan och beviljar prioriterad granskning för lecanemab för behandling av tidig Alzheimers sjukdom via det accelererade förfarandet
Regulatory Filings
2022-07-06 Swedish
Eisai slutför stegvis ansökan till FDA av lecanemab för behandling av tidig Alzheimers sjukdom via det accelererade förfarandet
Regulatory Filings
2022-05-10 Swedish
Eisai completes rolling submission to the FDA of lecanemab for early Alzheimer’s disease under the accelerated approval pathway
Regulatory Filings
2022-05-10 English
Kommuniké från årsstämma i BioArctic AB (publ)
AGM Information
2022-05-05 Swedish
Report from annual general meeting in BioArctic AB (publ)
AGM Information
2022-05-05 English
Interim / Quarterly Report 2022
Interim / Quarterly Report Q1 2022
2022-04-28 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Q1 2022
2022-04-28 English
AbbVie terminates collaboration with BioArctic on alpha-synuclein portfolio
Legal Proceedings Report
2022-04-20 English
AbbVie avslutar samarbetet med BioArctic kring alfa-synuklein-portföljen
M&A Activity
2022-04-20 Swedish
Notice of Annual General Meeting in BioArctic AB (Publ)
AGM Information
2022-04-06 English
Kallelse till årsstämma i BioArctic AB (publ)
AGM Information
2022-04-06 Swedish
Annual Report (ESEF) 2021
Annual Report (ESEF) FY 2021
2022-03-31 Swedish
The Nomination Committee's proposal for the election of board members in BioArctic AB
Board/Management Information
2022-03-09 English
Valberedningens förslag till val av styrelseledamöter i BioArctic AB
AGM Information
2022-03-09 Swedish
Eisai initiates submission of application data of lecanemab under the prior assessment consultation system in Japan with the aim of an earlier regulatory approval
Regulatory Filings
2022-03-04 English
Eisai påbörjar inlämning av lecanemab-data i Japan för förhandsgranskning, med ett tidigare regulatoriskt godkännande som mål
Regulatory Filings
2022-03-04 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Q4 2021
2022-02-03 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Q4 2021
2022-02-03 English